CN104981479B - 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病 - Google Patents

用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病 Download PDF

Info

Publication number
CN104981479B
CN104981479B CN201380072338.1A CN201380072338A CN104981479B CN 104981479 B CN104981479 B CN 104981479B CN 201380072338 A CN201380072338 A CN 201380072338A CN 104981479 B CN104981479 B CN 104981479B
Authority
CN
China
Prior art keywords
tat
disease
immunosuppressive
inflammation
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380072338.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104981479A (zh
Inventor
约舒华·高德博格
科林·比尔
克里斯托夫·霍兹-贝霍夫希奇
索菲·汉斯科姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruisilian Pharmaceutical Co ltd
Original Assignee
PIN Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PIN Pharma Inc filed Critical PIN Pharma Inc
Publication of CN104981479A publication Critical patent/CN104981479A/zh
Application granted granted Critical
Publication of CN104981479B publication Critical patent/CN104981479B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380072338.1A 2012-12-06 2013-12-06 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病 Active CN104981479B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734135P 2012-12-06 2012-12-06
US61/734,135 2012-12-06
US201361881266P 2013-09-23 2013-09-23
US61/881,266 2013-09-23
PCT/US2013/073658 WO2014089480A1 (en) 2012-12-06 2013-12-06 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides

Publications (2)

Publication Number Publication Date
CN104981479A CN104981479A (zh) 2015-10-14
CN104981479B true CN104981479B (zh) 2021-06-01

Family

ID=50884040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380072338.1A Active CN104981479B (zh) 2012-12-06 2013-12-06 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病

Country Status (13)

Country Link
US (3) US9878001B2 (https=)
EP (1) EP2928910B1 (https=)
JP (2) JP6607784B2 (https=)
CN (1) CN104981479B (https=)
AU (1) AU2013355039B2 (https=)
CA (1) CA2894166A1 (https=)
DK (1) DK2928910T3 (https=)
ES (1) ES2748423T3 (https=)
IL (1) IL239271B (https=)
NZ (1) NZ708836A (https=)
RU (1) RU2653754C2 (https=)
WO (1) WO2014089480A1 (https=)
ZA (1) ZA201504100B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016533352A (ja) * 2013-10-04 2016-10-27 ピーアイエヌ ファーマ インコーポレイテッド 免疫刺激性ＨＩＶ Ｔａｔ誘導体ポリペプチドによる癌の治療
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
CN110290799A (zh) * 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法
CA3192758A1 (en) * 2020-09-04 2022-03-10 Dompe' Farmaceutici Spa Peptides endowed with angiogenic activity
EP3964225A1 (en) * 2020-09-04 2022-03-09 Dompe' Farmaceutici S.P.A. Peptides endowed with angiogenic activity
US20230364112A1 (en) * 2020-09-29 2023-11-16 Alps Biotech Co., Ltd. Use of Antcin H and Its Derivatives for Treating Central Nervous System Diseases
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ， インコーポレイテッド Ａｌｓ患者の処置方法
WO2023062451A1 (en) * 2022-08-28 2023-04-20 Farhadi Andar Abi Ali Pegylated tat-efsevin-ta as an antiarrhythmic agent with favorable effect on heart failure caused by arrhythmia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405057A (zh) * 2009-03-23 2012-04-04 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2792206B1 (fr) 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
ATE465754T1 (de) 1999-08-12 2010-05-15 Inist Inc Nicht-immunsuppresives hiv tat-protein
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050244434A1 (en) 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20070248618A1 (en) 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
PL206097B1 (pl) 2001-05-03 2010-06-30 Fit Biotech Oyj Plc Wektor ekspresyjny, jego zastosowanie, sposób wytwarzania tego wektora, komórka gospodarza, kompozycja farmaceutyczna, szczepionka DNA, genowy czynnik terapeutyczny oraz sposób wytwarzania szczepionki DNA
US7927580B2 (en) 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
JP2016533352A (ja) * 2013-10-04 2016-10-27 ピーアイエヌ ファーマ インコーポレイテッド 免疫刺激性ＨＩＶ Ｔａｔ誘導体ポリペプチドによる癌の治療

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405057A (zh) * 2009-03-23 2012-04-04 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
tat protein[Human Immunodeficiency virus 1]，GenBank序列号ACN63364.1;Siddappa N B等;《GenBank数据库》;20090315 *

Also Published As

Publication number Publication date
WO2014089480A1 (en) 2014-06-12
AU2013355039B2 (en) 2017-08-24
EP2928910B1 (en) 2019-09-04
US20210069290A1 (en) 2021-03-11
EP2928910A4 (en) 2016-06-29
US20180185441A1 (en) 2018-07-05
ES2748423T3 (es) 2020-03-16
CA2894166A1 (en) 2014-06-12
EP2928910A1 (en) 2015-10-14
RU2653754C2 (ru) 2018-05-14
ZA201504100B (en) 2016-05-25
DK2928910T3 (da) 2019-10-07
JP2019163259A (ja) 2019-09-26
US20140178420A1 (en) 2014-06-26
US9878001B2 (en) 2018-01-30
NZ708836A (en) 2020-07-31
IL239271A0 (en) 2015-07-30
IL239271B (en) 2019-09-26
JP6607784B2 (ja) 2019-11-20
CN104981479A (zh) 2015-10-14
RU2015126776A (ru) 2017-01-13
HK1216318A1 (en) 2016-11-04
AU2013355039A1 (en) 2015-07-02
JP2016508121A (ja) 2016-03-17

Similar Documents

Publication Publication Date Title
CN104981479B (zh) 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
CN103476933B (zh) 白介素1受体的拮抗剂
JP2009525323A (ja) 神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法
TW201819398A (zh) 治療性肽
US20230046305A1 (en) Peptides and other agents for treating pain and increasing pain sensitivity
AU2010283169B2 (en) Novel peptide and use thereof
JP2018525337A (ja) 軽度認知障害の処置のためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の新規使用
CA2987365A1 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
KR101064914B1 (ko) 자가면역질환, 알러지성 질환 및 염증성 질환 치료용 약제 조성물 및 이의 전달 방법
US11628206B2 (en) Method for inhibiting STAT3 activity comprising administering Ssu72
JP5967448B2 (ja) ２型ｔｎｆ受容体の発現を誘導する合成ペプチド及びその利用
HK1216318B (en) Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
CN100348615C (zh) 抑制NF－κB和NFAT活化的基因及其编码的多肽
KR102530956B1 (ko) 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
US10125168B2 (en) Synthetic peptide for adjusting balance between presence of type 1 TNF receptor and type 2 TNF receptor and use thereof
WO2009091645A2 (en) Compositions and methods for treating chondrosarcomas
Eggleton et al. Autoimmune disease and calcium binding proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220316

Address after: USA New York

Patentee after: Ruisilian Pharmaceutical Co.,Ltd.

Address before: New York, United States

Patentee before: PIN PHARMA, Inc.